Michel Farnier
Overview
Explore the profile of Michel Farnier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
137
Citations
3613
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Azar Y, Ludwig T, Le Bon H, Strom T, Bluteau O, Di-Filippo M, et al.
Atherosclerosis
. 2024 Nov;
399:118596.
PMID: 39500114
Background And Aims: PCSK9 is a key regulator of LDL-cholesterol levels. PCSK9 gain of function variants (GOFVs) cause autosomal dominant hypercholesterolemia (ADH). The first described PCSK9-GOFV, p.Ser127Arg, almost exclusively reported...
2.
Nguyen M, Putot A, Masson D, Cottin Y, Gautier T, Tribouillard L, et al.
Front Cardiovasc Med
. 2024 Jul;
11:1419001.
PMID: 38984349
Background: There is increasing evidence regarding the association between endotoxemia and the pathogenesis of atherosclerosis and myocardial infarction (MI). During the acute phase of MI, endotoxemia might increase inflammation and...
3.
Dievart F, Bruckert E, Aboyans V, Bekka S, Boccara F, Bourdon Baron Munoz B, et al.
Arch Cardiovasc Dis
. 2024 May;
117(5):358-378.
PMID: 38762344
Low-density lipoprotein cholesterol has been established as a powerful cardiovascular risk factor; its reduction provides a clinical benefit in primary cardiovascular prevention, irrespective of the characteristics of the patients treated....
4.
Beliard S, Saheb S, Litzler-Renault S, Vimont A, Valero R, Bruckert E, et al.
Arterioscler Thromb Vasc Biol
. 2024 May;
44(6):1447-1454.
PMID: 38695169
Background: Patients with homozygous familial hypercholesterolemia (HoFH) remain at very high cardiovascular risk despite the best standard of care lipid-lowering treatment. The addition of evinacumab, an angiopoietin-like protein 3 monoclonal...
5.
Masson D, Leleu D, Farnier M, Chague F, Rampon C, Bichat F, et al.
Cardiovasc Res
. 2024 Jan;
120(2):111-113.
PMID: 38193579
No abstract available.
6.
Zeller M, Chague F, Maza M, Bichat F, Cottin Y, Farnier M
J Clin Lipidol
. 2023 Nov;
18(1):e38-e43.
PMID: 37985275
From a large regional registry, we aimed to address the characteristics and prognosis of patients with elevated triglycerides (TG) among patients hospitalized for an acute myocardial infarction (MI). From the...
7.
Raja V, Aguiar C, Alsayed N, Chibber Y, Elbadawi H, Ezhov M, et al.
Atherosclerosis
. 2023 Oct;
383:117312.
PMID: 37826864
Dyslipidemia refers to unhealthy changes in blood lipid composition and is a risk factor for atherosclerotic cardiovascular diseases (ASCVD). Usually, low-density lipoprotein-cholesterol (LDL-C) is the primary goal for dyslipidemia management....
8.
Kouame I, Farnier M, Chague F, Maza M, Bichat F, Zeller M, et al.
Eur J Prev Cardiol
. 2023 May;
30(17):e81-e83.
PMID: 37200491
No abstract available.
9.
Ferrieres J, Bruckert E, Farnier M, Krempf M, Mourad J, Roux B, et al.
J Comp Eff Res
. 2023 Mar;
12(4):e220181.
PMID: 36891969
This online interactive survey investigated lipid-lowering approaches of French cardiologists in high- and very high-cardiovascular risk patients with hypercholesterolemia. Physicians assessed three hypothetical patients at three clinic visits, and selected...
10.
Banach M, Penson P, Farnier M, Fras Z, Latkovskis G, Laufs U, et al.
Prog Cardiovasc Dis
. 2023 Mar;
79:2-11.
PMID: 36889490
Cardiovascular disease (CVD) is a chronic non-communicable disease (NCD) and the predominant cause of morbidity and mortality worldwide. Substantial reductions in the CVD prevalence have been achieved in recent years...